Mankind Pharma Limited — Updates, 31-07-2025: Press Release

Mankind Pharma reported robust Q1 FY26 results with revenue up 24.5% YoY to INR 3,570 Cr. Domestic sales increased 18.9%, while exports surged 81.1%, significantly boosted by BSV consolidation. EBITDA margin remained healthy at 23.8%. The company's domestic business outperformed the Indian Pharma Market, driven by strong growth in Chronic, Anti-infectives, and Respiratory segments. Consumer Healthcare revenue also rose 15%. Shareholders will receive an interim dividend of Re 1 per share. Diluted EPS for the quarter was INR 10.6.